anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Distal hypospadias accounts for the majority of hypospadias. Mathieu and Snodgrass techniques are widely used for repair of distal hypospadias but their comparative efficacy and reported outcomes are still debated. We conducted a systematic review and meta-analysis to compare the outcomes of these two techniques.
METHODS: Electronic databases and trial registries were searched for randomized controlled trials (RCTs) comparing Mathieu and Snodgrass techniques for primary distal hypospadias repair. Outcome measures included complication rates and cosmetic outcomes. Risk of bias assessment was performed using the ROB2. Data was analyzed using Review Manager 5.4; Trial Sequential Analysis (TSA) also was conducted for important outcomes.
RESULTS: Twelve RCTs were eligible for inclusion. The Snodgrass technique showed a significantly lower incidence of urethrocutaneous fistula (UCF) (RR 0.48, 95% CI [0.30-0.77]). However, there was no significant difference in the incidence of meatal stenosis (MS) between the two (RR 1.64, 95% CI [0.85-3.15]). TSA supports the findings for outcome UCF but not for MS. Operative time was shorter with the Snodgrass technique.
CONCLUSION: This SRMA indicates a lower incidence of UCF with Snodgrass technique compared to the Mathieu technique in distal hypospadias repair. However, there was no significant difference in the risk of MS.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of acute pulmonary embolism. According to current knowledge, it is caused by non-resolving fibrothrombotic obstructions of large pulmonary arteries. Some patients show an additional small vessel vasculopathy. Both kinds of obstruction lead to an increase in pulmonary vascular resistance (PVR), increase in mean pulmonary arterial pressure (mPAP), progressive right heart failure, and premature death if left untreated. Current guidelines recommend pulmonary endarterectomy (PEA) as the potentially curative treatment of first choice, which aims to remove fibrotic obstructions from the pulmonary vasculature. The survival of patients undergoing PEA surgery ranges between 76 and 91% after 3 years, which is superior to medical treatment in inoperable CTEPH patients. The majority of operated patients experience almost complete normalisation of haemodynamics and improvements in symptoms. However, 17-51% of operated patients will develop persistent or recurrent pulmonary hypertension (PH). Some patients remain limited in their exercise capacity and prognosis. As patients are monitored on an intensive care unit immediately after PEA, immobilisation after the operation may lead to further peripheral deconditioning. A recent study of 251 CTEPH patients with follow-up until 12 months after PEA showed a persistent exercise limitation in almost 40% of patients despite normalisation of PVR and haemodynamics. This limitation was characterised by a multifactorial aetiology also involving respiratory function abnormalities. Previous studies in patients with inoperable or persistent CTEPH have suggested beneficial effects of exercise training as an add-on to targeted medical therapy, increasing exercise capacity, and quality of life (QoL). However, it is not known, whether early rehabilitation with exercise treatment is safe, feasible, and may further improve exercise capacity after PEA. Prospective studies on exercise training for CTEPH patients shortly after PEA surgery are lacking. Furthermore, to the best of our knowledge, there have been no studies yet describing the early effect within the first weeks after PEA. The aim of this study was therefore to assess the feasibility of supervised exercise training in CTEPH patients shortly after PEA. Furthermore, changes of haemodynamic and clinical parameters including oxygen uptake, QoL, exercise capacity, and right heart function assessed by echocardiography and right heart catheterisation were obtained before and shortly after PEA.
Temozolomide-based radiochemotherapy (TMZ/RT=\>TMZ) represents the standard of care for patients with newly diagnosed glioblastoma. In this study, pembrolizumab will be administered (200 mg every 3 weeks) in addition to TMZ/RT=\>TMZ.
No medications have been reported to inhibit the progression of aortic valve stenosis (AS). The present study aimed to investigate whether evolocumab use is related to the slow progression of AS evaluated by serial echocardiography. This was a retrospective observational study from 2017 to 2022 at Yokohama City University Medical Center. Patients aged ≥ 18 with moderate AS were included. Exclusion criteria were (1) mild AS; (2) severe AS defined by maximum aortic valve (AV) velocity ≥ 4.0 m/s; and/or (3) no data of annual follow-up echocardiography. The primary endpoint was the association between evolocumab use and annual changes in the maximum AV-velocity or peak AV-pressure gradient (PG). A total of 57 patients were enrolled: 9 patients treated with evolocumab (evolocumab group), and the other 48 patients assigned to a control group. During a median follow-up of 33 months, the cumulative incidence of AS events (a composite of all-cause death, AV intervention, or unplanned hospitalization for heart failure) was 11% in the evolocumab group and 58% in the control group (P = 0.012). Annual change of maximum AV-velocity or peak AV-PG from the baseline to the next year was 0.02 (- 0.18 to 0.22) m/s per year or 0.60 (- 4.20 to 6.44) mmHg per year in the evolocumab group, whereas it was 0.29 (0.04-0.59) m/s per year or 7.61 (1.46-16.48) mmHg per year in the control group (both P < 0.05). Evolocumab use was associated with slow progression of AS and a low incidence of AS events in patients with moderate AS.
The toxicity of botulinum multi-domain neurotoxins (BoNTs) arises from a sequence of molecular events, in which the translocation of the catalytic domain through the membrane of a neurotransmitter vesicle plays a key role. A recent structural study of the translocation domain of BoNTs suggests that the interaction with the membrane is driven by the transition of an α helical switch towards a β hairpin. Atomistic simulations in conjunction with the mesoscopic Twister model are used to investigate the consequences of this proposition for the toxin-membrane interaction. The conformational mobilities of the domain, as well as the effect of the membrane, implicitly examined by comparing water and water-ethanol solvents, lead to the conclusion that the transition of the switch modifies the internal dynamics and the effect of membrane hydrophobicity on the whole protein. The central two α helices, helix 1 and helix 2, forming two coiled-coil motifs, are analyzed using the Twister model, in which the initial deformation of the membrane by the protein is caused by the presence of local torques arising from asymmetric positions of hydrophobic residues. Different torque distributions are observed depending on the switch conformations and permit an origin for the mechanism opening the membrane to be proposed.
Arm 2 - Lobular Breast Cancer cohort (n=29 participants) will be treated with combination therapy. The combination therapy includes; Crizotinib Oral Capsule \[Xalkori\] (250mg b.d.) plus Fulvestrant 50 mg/mL Prefilled Syringe \[Faslodex or generic\] intramuscular (IM) injection (500 mg per 1 cycle (q28 days, plus loading dose on day 15).
Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically correct direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.
After a 1-week washout period avoiding consumption of tomato, tomato-based products and other food sources of lycopene (watermelon, papaya, grapefruit and lycopene supplements), participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during 3 months (intervention). Then they will return to their regular dietary pattern during 3 weeks. At the beginning of the first 4 month, participants will be encouraged to move into the second phase (control), before a 1-week washout period. The second phase or control consists in following their regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during the next 3 months.
The invention relates to use of a pro-inflammatory agent such as IL-8 or muramyl dipeptide (MDP) for the manufacture of a medicament for Crohn's disease. Preferably the pro-inflammatory agent is a neutrophil chemoattractant. Preferably the pro- inflammatory agent is EL-8. The invention also relates to a method of treating Crohn's disease in a subject, said method comprising administering to said subject an effective amount of a pro-inflammatory agent such as IL-8, and to IL-8 for use in the treatment of Crohn's disease. The invention also relates to products comprising IL-8 for topical treatment. The invention also relates to methods for determining the responsiveness of a subject to MDP comprising determining the CARD15 genotype of the subject.
In the present invention, there is described a highly stable liquid formulation having broad spectrum preservative properties which constitutes an admixture of a dialkanol-substituted dimethylhydantoin, an iodopropynyl compound, a stabilizer of a hydantoin, urea or derivative thereof, and a hydroxyl solvent. Preferably, the constituents are dimethyloldimethylhydantoin, 3-iodo-2-propynylbutyl carbamate, dimethylhydantoin, and a glycol solvent. The preservative preferably has a total formaldehyde content of 5 to 25 percent and less than 1 percent of free formaldehyde. The composition is prepared by successively admixing the dialkanol-substituted dimethylhydantoin and the stabilizer, the hydroxyl solvent, and the iodopropynyl compound. Also described is a stabilized iodopropynyl compound preferably containing dimethylhydantoin as the stabilizer. Killing or slowing growth of microbes is achieved by treating a solution being subjected to microbe growth with the above-described formulation.
The invention discloses a liver-protecting and lipid-lowering scented tea and a making method thereof. The liver-protecting and lipid-lowering scented tea comprises the following raw materials by weight: 15-25 parts of marigolds, 15-20 parts of Hangzhou white chrysanthemum, 10-15 parts of white plum blossoms, 8-12 parts of sorghum powder, 7-10 parts of chestnut kernel, 6-9 parts of longan, 5-7 parts of gynostemma pentaphyllum, 4-6 parts of ganoderma lucidum, 5-7 parts of phellodendron Chinese schneid, 4-6 parts of eucommia ulmoides oliver, 3-5 parts of semen sinapis, 5-7 parts of black Chinese wolfberry, 4-6 parts of Medoggreenpit-viper, 3-5 parts of liquorice, 5-7 parts of laver, 4-6 parts of pachyrhizus erosus starch, 5-7 parts of grape seed extract, 4-6 parts of tomato extract, 5-7 parts of cashew nuts, 3-5 parts of hawthorn, 5-8 parts of Pu'er tea, 2-4 parts of rice nectar, and 5-10 parts of composite powder. The health care scented tea of the invention is fragrant and tasty, and exquisite and silky. Through scientific compatibility, the scented tea is nutritionally balanced. Through collocation of a variety of medicinal and edible traditional Chinese herbal medicines, the scented tea has good effects of beautifying and skin nourishing, kidney nourishing and eyesight improving, and the like, and can reduce the content of blood lipid and balance blood lipid. Moreover, the scented tea can effectively prevent and treat the symptoms of patients with cardiovascular disease, obesity, hyperlipidemia, or the like.
FIELD: medicine. SUBSTANCE: set is applied in quantitatively determining the contents of autoantibodies to synthetic fragment of phencyclidine-binding membrane protein (PBM) of human brain in human blood serum in cases of cerebral ischemia by means of immunoenzyme assay. The PMB is a component of complex receptor protein of neuron membranes, injured function of which can lead to pathologic changes in the central nerve system. The level of autoantibodies to PMB in blood serum correlates with availability and predisposition to cerebral ischemia. EFFECT: enhanced effectiveness in diagnosing cerebral ischemia cases. 12 cl
FIELD: medicine. SUBSTANCE: method involves determining spectral density of power in the range of very high frequencies with hyperergic, normergic and hypoergic types of response being detected. Hyperergic response type being found and spectral density of power being greater than 130 ms 2 , Dalargin is intravenously administered at a single bolus dose of 1-2 mg/kg of body mass. Hypoergic response type being found and spectral density of power being less than 25 ms 2 , Neoton is administered as infusion at a single bolus dose of 60 mg/kg of body mass. EFFECT: enhanced effectiveness of treatment. 3 tbl
1527660 Stable solid dosage forms containing metrifonate BAYER AG 30 Sept 1976 [2 Oct 1975] 40624/76 Heading A5B Pharmaceutical compositions for combatting bilharziosis consist of solid enterally administrable forms (e.g. granules, powders, capsules, coated tablets, pills, suppositories, and preferably tablets) containing metrifonate (i.e. 0, 0-dimethyl-(1-hydroxy-2, 2, 2-trichloroethyl) phosphonate) and one or more substantially neutral inert additives comprising a material having a water content of at most 3% by weight or in which the water is so firmly bound to the material that it cannot be released at a temperature of 35‹C or below, the composition having a free water content of at most 2.5% by weight and a pH value (i.e. the pH of an aqueous mixture of 10 parts by weight of the composition suspended in 100 parts of distilled water) of 6.5 to 7.5. Suitable inert additives are mono- or poly-saccharides, silica, a neutral amino-acid, a neutral inorganic or organic salt of an alkali metal or alkaline earth metal, cellulose, and polyvinyl pyrrolidone. The compositions may also contain suitable buffers or buffer systems. The compositions are said to have improved stability on storage.
PURPOSE:To prepare a composition for oral cavity application, effective to improve the acid resistance of the tooth for a long period, easily giving a preparation having excellent feeling to the mouth, and useful as toothpaste, etc., by the use of a hardly soluble stannous compound, a soluble fluorine compound free of tin ions, and a phytic acid compound. CONSTITUTION:A composition for oral cavity application containing (A) a hardly soluble stannous compound (e.g. stannous pyrophosphate) a part of which exists pref. as precipitate, (B) a soluble fluorine compound free of tin ions (e.g. sodium fluoride), and (C) a phytic acid compound (e.g. phytic acid). The amounts of (A), (B) and (C) are pref. 0.2-10wt% as tin, 100-10,000ppm as fluorine ion, and 0.1-20wt% (especially 0.2-10wt%), respectively. The pH value of the composition is pref. 2-7, especially 3-6. The composition exhicits excellent effect to improve the acid resistance of the tooth, and keeps the effect for a long period. It gives excellent feeling to the mouth, and there is little restrictions in the preparation.
One of the challenges in effective combination therapy in HIV-infected patients is the ability to achieve immune reconstitution. IL-2 is hypothesized to restore and/or preserve the immune system when added to potent antiretroviral regimens. This study will evaluate restoration of immune functions of CD4 cells and will also determine the best way to deliver IL-2 in a safe and effective way.

Part I: Patients add a 5-day course of subcutaneous IL-2 every 8 weeks for up to 48 weeks (6 cycles) to their HAART therapy. Three dose levels of IL-2 are administered. \[AS PER AMENDMENT 5/3/01: It is strongly recommended, but not required, that\] the first and second cycles of IL-2 are given in the hospital on an inpatient basis. The parent or patient is trained to give the injections and has the option of administering subsequent injections at home. Patients are monitored for CD4 and CD8 cell count and viral load. Enrollment into Part 1 begins at the lowest dose level; assuming no serious toxicities (Grade 3 or higher) occur, patients are enrolled into higher dose levels. The highest tolerated dose is established.

Part 2: After the highest tolerated dose is established in Part 1, additional patients are randomized to receive HAART alone (Arm 1), HAART with high-dose IL-2 (Arm 2), or HAART with low-dose IL-2 (Arm 3). High-dose IL-2 is given twice daily at the highest dose tolerated in Part 1 for 5 days every 8 weeks for 6 cycles. Low-dose IL-2 is given once a day every day for 48 weeks. For Arms 2 and 3 \[AS PER AMENDMENT 5/3/01: (except patients in the pharmacokinetic substudy), it is strongly recommended, but not required, that\] IL-2 is given the first week on an inpatient basis by hospital personnel. As in Part 1, there is the option of administering the remaining injections at home. Intensive toxicity monitoring, routine lymphocyte subsets, and quantitative HIV RNA are performed on all patients at specified time points during the study. The first 12 patients in Arms 2 and 3 have pharmacokinetic testing with frequent blood samples drawn at intervals, some of which require staying up to 12 hours at the clinic. Diphtheria/tetanus immunizations and bacteriophage phi X174 immunizations are administered to all patients to determine antibody responses.
The invention provides a human cell with low immunogenicity and a preparation method thereof. Specifically, the invention relates to a modified human cell, and compared with corresponding wild type cells, the human leukocyte antigen (HLA) protein or polypeptide on the cell surface undergoes deletion or down-regulation of expression, so that the modified human cell has reduced immunogenicity. The invention also relates to a preparation method of the modified human cell. The method includes enabling deletion or down-regulation of expression of one or more genes (e.g. beta2-microglobulin gene) in the biosynthesis or transport way of HLA in the human cell. The modified human cell (line) provided by the invention has low immunogenicity, and is expected to become a novel transplantation donor able to reduce or even avoid immunological rejection, thus providing a brand new material and method for organ transplantation.
Uterine peristalsis imaging (UPI) can provide objective, quantitative measures of uterine peristalsis (UP). Unlike other modalities, the contractile activity seen during UP can be quantitatively measured and reliably observed with UPI. With 3D accuracy, which takes into consideration the individual's unique uterine anatomy, the site of initiation and termination of the contraction are mapped along with the characterization of the direction, duration, and magnitude of the contractile forces. Novel peristalsis indices were developed for quantitative characterization of uterine contractile patterns. This includes measuring the duration and magnitude of UP. This assessment can be performed in a noninvasive way with little patient discomfort for a prolonged period.
Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
Two hundred and sixty-three patients with BPPV (2009-2014), confirmed by videonystagmography (VNG), were enrolled in the study. Patients' charts were reviewed. They were grouped as those with or without migraine. Distribution of gender, age, duration of symptoms and affected side were reviewed. Two hundred and thirty-one patients with no migraine were identified.
BACKGROUND: Machine learning (ML) approaches have become increasingly popular in predicting surgical outcomes. However, it is unknown whether they are superior to traditional statistical methods such as logistic regression (LR). This study aimed to perform a systematic review and meta-analysis to compare the performance of ML vs LR models in predicting postoperative outcomes for patients undergoing gastrointestinal (GI) surgery.
METHODS: A systematic search of Embase, MEDLINE, Cochrane, Web of Science, and Google Scholar was performed through December 2022. The primary outcome was the discriminatory performance of ML vs LR models as measured by the area under the receiver operating characteristic curve (AUC). A meta-analysis was then performed using a random effects model.
RESULTS: A total of 62 LR models and 143 ML models were included across 38 studies. On average, the best-performing ML models had a significantly higher AUC than the LR models (ΔAUC, 0.07; 95% CI, 0.04-0.09; P < .001). Similarly, on average, the best-performing ML models had a significantly higher logit (AUC) than the LR models (Δlogit [AUC], 0.41; 95% CI, 0.23-0.58; P < .001). Approximately half of studies (44%) were found to have a low risk of bias. Upon a subset analysis of only low-risk studies, the difference in logit (AUC) remained significant (ML vs LR, Δlogit [AUC], 0.40; 95% CI, 0.14-0.66; P = .009).
CONCLUSION: We found a significant improvement in discriminatory ability when using ML over LR algorithms in predicting postoperative outcomes for patients undergoing GI surgery. Subsequent efforts should establish standardized protocols for both developing and reporting studies using ML models and explore the practical implementation of these models.
PURPOSE:To substantially eliminate the generation of non-specific reaction by using IgA, IgE or IgD as an antibody in immunoassay. CONSTITUTION:Fab fractions and Fc fractions exist in IgG and the factors such as rheumatoid factors which are the cause for the non-specific reaction are bound with such Fc fractions. The non-specific reaction is considered to be induced by such binding. In contrast therewith, the rheumatoid factors, etc. do not bind with the Fc fractions of IgA, IgE and IgD and the non-specific reaction is not induced. Therefore, this antibody is characterised by the non-use of IgG and even in the case of utilizing a mixture of immune globulin, the mixture is used after IgG is removed therefrom as far as possible.
For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps \> 2mm and large needle holes \> 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.